Teva Pharmaceutical Industries Ltd. is in the midst of making big changes that management believes will position it for sustainable long-term growth. As part of the new strategy, Teva is preparing for the integration of Allergan PLC’s generic drug business, setting up to launch several brand drugs from its newly pruned specialty pipeline, and managing 17 projects in a budding area for the company, new therapeutic entities (NTEs), medicines that bridge generics and specialty.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?